The VMA system monitors heart, respiration rates and movement without pressure pads, sensors or cuffs that touch the patient.

The VMA includes alerts for fall prevention, pressure ulcer prevention and deteriorating heart and respiratory readings, thus improving patient care at the bedside.

The VMA system utilizes the company’s telemedicine technology and makes possible the extension of large scale monitoring to the aging population, as well as in long-term care facilities and home care.

Sensiotec CTO and Georgia Institute of Technology Smart Antenna Laboratory founder and director Mary Ann Ingram said, "With our patented Ultra-wideband technology, science fiction has become fact."

Sensiotec CEO Robert Arkin said, "We’re excited by the opportunity with the Virtual Medical Assistant to make a difference in people’s lives through improved disease management, while also addressing society’s need to help contain healthcare costs."

Sensiotec said the VMA technology has received the US Food and Drug Administration 510(k) class II pre-market clearance and is in market trials.